The startup develops a proprietary implant technology that delivers drugs directly to targeted retinal tissues, aimed at preventing blindness in patients with intermediate-stage retinal diseases. This platform focuses on creating safe, durable, and minimally invasive therapeutic options for ophthalmology.
Funding
$5.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for retinal diseases like Diabetic Macular Edema (DME) and intermediate AMD often require frequent intravitreal injections, which can be painful, inconvenient, and associated with compliance issues, while also lacking long-term efficacy. This creates a need for more durable and less invasive drug delivery methods to improve patient outcomes and reduce the burden of care.
Solution
Vinci Pharmaceuticals is developing EPIPLANT™, a proprietary, needle-free platform technology for targeted drug delivery to the retina. EPIPLANT™ aims to provide a safe and effective alternative to traditional injections, offering sustained therapeutic release directly to the affected retinal tissues. This innovative approach seeks to improve treatment durability, reduce the frequency of clinical visits, and enhance patient adherence, ultimately preventing vision loss associated with retinal diseases. The platform has a clear regulatory pathway and strong IP protection.
Target Audience
The primary target audience includes ophthalmologists and retinal specialists seeking innovative drug delivery solutions, as well as patients with retinal diseases such as Diabetic Macular Edema (DME) and intermediate AMD.
Features
- Needle-free drug delivery system for retinal therapies
- Targeted drug release directly to affected retinal tissues
- Designed for improved durability and reduced injection frequency
- Potential for enhanced patient compliance and reduced burden of care
- Addresses Diabetic Macular Edema (DME) and Intermediate AMD (iAMD)